Insmed Incorporated (NASDAQ:INSM – Get Free Report) was the recipient of a significant growth in short interest in the month of May. As of May 15th, there was short interest totalling 9,930,000 shares, a growth of 16.4% from the April 30th total of 8,530,000 shares. Based on an average daily volume of 1,760,000 shares, the […]
Insmed (NASDAQ:INSM – Free Report) had its price target lifted by HC Wainwright from $52.00 to $70.00 in a research note issued to investors on Wednesday, Benzinga reports. The firm currently has a buy rating on the biopharmaceutical company’s stock. HC Wainwright also issued estimates for Insmed’s FY2025 earnings at ($3.54) EPS, FY2026 earnings at […]
Insmed Incorporated (NASDAQ:INSM – Get Free Report) CFO Sara Bonstein sold 220,564 shares of Insmed stock in a transaction on Wednesday, May 29th. The stock was sold at an average price of $50.00, for a total transaction of $11,028,200.00. Following the completion of the transaction, the chief financial officer now owns 117,481 shares in the […]
Insmed (NASDAQ:INSM – Get Free Report) had its price objective increased by investment analysts at HC Wainwright from $52.00 to $70.00 in a research note issued on Wednesday, Benzinga reports. The brokerage currently has a “buy” rating on the biopharmaceutical company’s stock. HC Wainwright’s price target would suggest a potential upside of 22.85% from the […]
Bank of America reaffirmed their buy rating on shares of Insmed (NASDAQ:INSM – Free Report) in a research note issued to investors on Tuesday morning, Benzinga reports. Bank of America currently has a $40.00 target price on the biopharmaceutical company’s stock. A number of other brokerages have also weighed in on INSM. Barclays raised their […]